Kymera Therapeutics (NASDAQ:KYMR) COO Sells $349,080.82 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 4,279 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $81.58, for a total transaction of $349,080.82. Following the sale, the chief operating officer owned 44,018 shares of the company’s stock, valued at approximately $3,590,988.44. The trade was a 8.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Stock Down 0.0%

NASDAQ KYMR opened at $81.42 on Friday. The firm has a market cap of $6.70 billion, a price-to-earnings ratio of -22.81 and a beta of 2.06. The company has a 50-day simple moving average of $83.33 and a two-hundred day simple moving average of $79.31. Kymera Therapeutics, Inc. has a 12-month low of $28.50 and a 12-month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. During the same period in the prior year, the business posted ($0.82) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. Equities analysts expect that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors have recently bought and sold shares of KYMR. Smartleaf Asset Management LLC raised its stake in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC raised its stake in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares in the last quarter. Bessemer Group Inc. raised its stake in Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the fourth quarter worth about $63,000.

Analyst Ratings Changes

KYMR has been the subject of a number of recent analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. UBS Group upped their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, BTIG Research lowered their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.